Last reviewed · How we verify
NCT04141800: SPANIK-HF
Spanish Study of Hyperkalaemia Incidence and Prognosis in Patients With Heart Failure and Reduced Ejection Fraction
trial in Heart Failure With Reduced Ejection Fraction in 565 participants. Completed in 31 March 2021.
31 March 2021
Quick facts
| Lead sponsor | Spanish Society of Cardiology |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 565 |
| Start date | 30 April 2019 |
| Primary completion | 31 March 2021 |
| Estimated completion | 31 March 2021 |
| Sites | 1 location across Spain |
Conditions studied
- Heart Failure With Reduced Ejection Fraction — all drugs for Heart Failure With Reduced Ejection Fraction →
- Hyperkalemia — all drugs for Hyperkalemia →
Sponsor
Spanish Society of Cardiology
Who can join
18 and older, any sex, with Heart Failure With Reduced Ejection Fraction or Hyperkalemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
* Participant centres and researchers: 20 National Public Health System hospitals. Cardiology specialist physicians * Clinical Research Ethics Committee (CREC): Hospital 12 de Octubre, Madrid \- Main goal: To estimate prevalence and, in medium term basis (12 months), incidence of hyperkalaemia in heart failure (HF) outpatients with reduced ejection fraction (REF) and its relationship with non-optimal HF therapy and clinical outcomes (mortality and hospital admission). \- Study design: National multicentric prospective observational study that includes 12 months follow-up of consecutive cases of HF outpatients with REF. Inclusion baseline visit and follow -up visits at 12 months will be scheduled for collecting clinical and blood sample data of patients. \- Study population: The expected number of patients recruited in 20 Spanish research centres is 600.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics.
Delgado-Jiménez JF, Segovia-Cubero J, Almenar-Bonet L, de Juan-Bagudá J, et al · · 2022 · cited 1× · PMID 35268260 · DOI 10.3390/jcm11051170
Verify or expand the search:
- PubMed search for NCT04141800
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure With Reduced Ejection Fraction
Currently open trials in the same condition.
- NCT07465653 — A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction · Phase 1 · recruiting
- NCT07465679 — A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treat · active not recruiting
- NCT07275931 — Digital Support Program for Patients With Heart Failure - a Cluster-Randomized Hybrid Type 2 Study · NA · recruiting
- NCT06942221 — Digital Solutions in Heart Therapy (DIGNITY) · NA · recruiting
- NCT07087613 — Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG · recruiting
Other Spanish Society of Cardiology trials
Trials by the same sponsor.
- NCT06755801 — Nebivolol ANOCA Treatment Randomized Trial · Phase 3 · not yet recruiting
- NCT05619601 — Gender Differences in Prevention Strategies and Therapeutic Adherence After Acute Myocardial Infarction · active not recruiting
- NCT04674475 — OPTImized Coronary Interventions eXplaIn the bEst cliNical outcomEs · unknown
- NCT05825339 — Absolute Flow for Ischemia With No Obstructive Coronary Arteries · unknown
- NCT04850417 — Randomized Study of Beta-Blockers and Antiplatelets in Patients With Spontaneous Coronary Artery Dissection · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04141800 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Spanish Society of Cardiology
- Last refreshed: 25 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04141800.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing